Published in Nature on February 15, 2012
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Mitochondria and cancer. Nat Rev Cancer (2012) 4.81
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77
Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature (2015) 3.64
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 3.55
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell (2012) 2.85
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Influence of metabolism on epigenetics and disease. Cell (2013) 2.64
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med (2015) 2.53
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev (2013) 2.12
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev (2012) 2.10
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov (2012) 1.94
Oncometabolites: linking altered metabolism with cancer. J Clin Invest (2013) 1.78
Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature (2016) 1.67
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell (2015) 1.58
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist (2016) 1.51
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res (2012) 1.46
Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab (2015) 1.45
Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab (2014) 1.45
HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biol (2013) 1.45
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
Understanding metabolic regulation and its influence on cell physiology. Mol Cell (2013) 1.43
Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A (2014) 1.36
What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol (2013) 1.36
Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metab (2015) 1.34
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep (2013) 1.32
Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J Clin Invest (2013) 1.28
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov (2014) 1.26
Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet (2014) 1.24
Defects in mitochondrial metabolism and cancer. Cancer Metab (2014) 1.24
bHLH-PAS proteins in cancer. Nat Rev Cancer (2013) 1.23
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell (2014) 1.23
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res (2014) 1.19
TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev (2015) 1.18
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. Int J Cell Biol (2012) 1.17
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol (2012) 1.17
Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chem Biol (2014) 1.15
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem (2014) 1.15
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol (2013) 1.15
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) (2012) 1.13
Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem (2014) 1.11
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia (2013) 1.11
S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate. Nature (2016) 1.11
Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. Am J Hum Genet (2013) 1.09
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev (2014) 1.09
Genetically-defined metabolic reprogramming in cancer. Trends Endocrinol Metab (2012) 1.09
Fundamentals of cancer metabolism. Sci Adv (2016) 1.09
A metabolic signature for long life in the Caenorhabditis elegans Mit mutants. Aging Cell (2013) 1.06
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem (2012) 1.06
Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol (2013) 1.04
Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol (2015) 1.03
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem (2014) 1.03
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem (2013) 1.03
Mitochondria and Cancer. Cell (2016) 1.02
New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci (2015) 1.00
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol (2015) 0.99
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem (2015) 0.99
The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms. Front Oncol (2013) 0.98
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev (2014) 0.97
A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov (2014) 0.95
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. Oncologist (2014) 0.94
Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol (2015) 0.93
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat Commun (2014) 0.93
Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol (2013) 0.92
Metabolic mechanisms of epigenetic regulation. ACS Chem Biol (2013) 0.92
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. Acta Neuropathol Commun (2013) 0.91
Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther (2015) 0.90
Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci (2015) 0.90
MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma. Oncogene (2014) 0.90
Glutaminolysis feeds mTORC1. Cell Cycle (2012) 0.89
Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors. J Med Chem (2013) 0.89
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res (2015) 0.89
Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget (2015) 0.88
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep (2015) 0.88
2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab (2015) 0.87
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica (2015) 0.87
A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiol Dis (2012) 0.87
Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. Cell Cycle (2014) 0.86
Alterations of 5-hydroxymethylcytosine in human cancers. Cancers (Basel) (2013) 0.85
Metabolism: unmasking an oncometabolite. Nat Rev Cancer (2012) 0.85
R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell (2013) 0.85
An epigenetic gateway to brain tumor cell identity. Nat Neurosci (2015) 0.85
EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer. EMBO J (2015) 0.85
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. Int J Cell Biol (2012) 0.85
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia (2015) 0.85
Oncometabolites: tailoring our genes. FEBS J (2015) 0.85
Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J (2017) 0.85
Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol (2013) 0.85
Successive distinct high-grade gliomas in L-2-hydroxyglutaric aciduria. J Inherit Metab Dis (2014) 0.84
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun (2015) 0.84
D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nat Commun (2015) 0.83
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathol Commun (2014) 0.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature (2010) 18.63
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat Chem Biol (2009) 8.36
Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20
Modified procedure for the assay of H-3-or C-14-labeled hydroxyproline. Anal Biochem (1966) 5.08
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep (2011) 4.89
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res (2004) 3.46
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A (2006) 2.90
DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst (2010) 2.87
Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem (2006) 2.86
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Posttranslational enzymes in the biosynthesis of collagen: intracellular enzymes. Methods Enzymol (1982) 2.77
An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res (2009) 2.69
Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure (2009) 2.59
Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol (2008) 2.47
Genetic knockouts and knockins in human somatic cells. Nat Protoc (2007) 2.21
Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem (2003) 2.11
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One (2011) 2.00
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell (2003) 1.85
Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem Biol (2007) 1.84
MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol (2011) 1.81
Improved methods for the generation of human gene knockout and knockin cell lines. Nucleic Acids Res (2005) 1.75
Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J (2005) 1.62
Metabolomics-driven quantitative analysis of ammonia assimilation in E. coli. Mol Syst Biol (2009) 1.57
L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology (2004) 1.36
The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J Biol Chem (2006) 1.35
Cloning of the human prolyl 4-hydroxylase alpha subunit isoform alpha(II) and characterization of the type II enzyme tetramer. The alpha(I) and alpha(II) subunits do not form a mixed alpha(I)alpha(II)beta2 tetramer. J Biol Chem (1997) 1.34
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathol (2010) 1.22
Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene (2007) 1.22
Unifying gene expression measures from multiple platforms using factor analysis. PLoS One (2011) 1.06
The active site of an algal prolyl 4-hydroxylase has a large structural plasticity. J Biol Chem (2007) 1.06
Intracellular alpha-ketoglutarate controls the efficacy of renal organic anion transport. J Pharmacol Exp Ther (1995) 1.04
Medulloblastoma in a child with the metabolic disease L-2-hydroxyglutaric aciduria. Pediatr Neurosurg (2002) 1.03
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet (2011) 6.98
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol (2007) 5.53
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature (2003) 5.04
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 4.78
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A (2002) 4.03
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer (2009) 3.90
Pregnancy-stimulated neurogenesis in the adult female forebrain mediated by prolactin. Science (2003) 3.90
A tweezers-like motion of the ATP-binding cassette dimer in an ABC transport cycle. Mol Cell (2003) 3.88
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev (2005) 3.88
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science (2002) 3.86
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science (2013) 3.72
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature (2004) 3.63
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol (2011) 3.57
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov (2011) 3.45
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Single-layer MoS2 phototransistors. ACS Nano (2011) 3.43
FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell (2009) 3.37
Probe selection for high-density oligonucleotide arrays. Proc Natl Acad Sci U S A (2003) 3.31
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res (2006) 3.06
Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. J Neurosci (2004) 3.00
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst (2010) 3.00
Gene structure-based splice variant deconvolution using a microarray platform. Bioinformatics (2003) 2.97
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol (2008) 2.93
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron (2012) 2.84
Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol (2013) 2.84
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood (2007) 2.77
Comparative and functional genomic analyses of the pathogenicity of phytopathogen Xanthomonas campestris pv. campestris. Genome Res (2005) 2.65
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Male pheromone-stimulated neurogenesis in the adult female brain: possible role in mating behavior. Nat Neurosci (2007) 2.55
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 2.35
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med (2013) 2.31
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol (2011) 2.27
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2010) 2.21
Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell (2009) 2.18
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet (2006) 2.10
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One (2011) 2.00
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 1.98